Holen Sie sich die Stockscreener-App
4.26
0.47%
-0.02
Handel nachbörslich:
4.14
-0.12
-2.82%
Schlusskurs vom Vortag:
$4.28
Offen:
$4.0666
24-Stunden-Volumen:
841
Relative Volume:
0.03
Marktkapitalisierung:
$33.58M
Einnahmen:
$2.34M
Nettoeinkommen (Verlust:
$-24.85M
KGV:
-1.228
EPS:
-3.4691
Netto-Cashflow:
$-23.25M
1W Leistung:
-10.32%
1M Leistung:
-9.02%
6M Leistung:
-20.08%
1J Leistung:
-26.55%
1-Tages-Spanne:
$4.0666
$4.26
1-Wochen-Bereich:
$3.62
$4.95
52-Wochen-Spanne:
$3.4962
$11.00
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Firmenname
Radiopharm Theranostics Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie RADX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
4.26 | 33.74M | 2.34M | -24.85M | -23.25M | -3.4691 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-12 | Eingeleitet | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Aktie (RADX) Neueste Nachrichten
Radiopharm Theranostics Announces Successful General Meeting Resolutions - TipRanks
B. Riley Lowers Radiopharm Theranostics (NASDAQ:RADX) Price Target to $13.00 - Defense World
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer - Sahm
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC) - The Globe and Mail
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Globe and Mail
Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Resolutions - MSN
Radiopharm Theranostics Limited: Promising Financial and Clinical Outlook Justifies Buy Rating - TipRanks
Radiopharm (ASX:RAD, Nasdaq:RADX) to Showcase Oncology Pipeline at Deutsche Bank ADR Conference - Kalkine Media
Radiopharm Theranostics to Present at Deutsche Bank ADR Virtual Investor Conference - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Perspective Therapeutics (CATX) - The Globe and Mail
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Globe and Mail
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
International companies to host live webcasts at Deutsche - GlobeNewswire
Radiopharm Theranostics Announces November AGM with Key Resolutions - MSN
Radiopharm Theranostics secures A$35 million in private placement - Investing.com India
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV) - The Globe and Mail
Radiopharm Theranostics Accelerates RAD202 Clinical Trial Following Positive Safety Review - MSN
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Radiopharm Theranostics Limited: Strategic Advancements and Financial Stability Support Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Radiopharm Theranostics Hosts Webinar Series on Radiopharmaceutical Therapies - MSN
Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating - TipRanks
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody By Investing.com - Investing.com India
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody - Investing.com
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) By Investing.com - Investing.com India
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) - Investing.com
Radiopharm Theranostics Receives FDA Investigational New Drug Clearance for RV-01 Cancer Therapy - new.smallcaps.com.au
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewswire Inc.
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board By Investing.com - Investing.com India
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board - Investing.com
Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Brookline Capital Management - Defense World
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital - Investing.com
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital By Investing.com - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive By Investing.com - Investing.com South Africa
Finanzdaten der Radiopharm Theranostics Ltd Adr-Aktie (RADX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):